Anaplastic thyroid carcinoma is an extremely aggressive and rare malignant neoplasm that originates from thyroid tissue and represents the most undifferentiated form with the poorest prognosis among thyroid tumors. It is characterized by a complete loss of the features of follicular differentiation, with absence of the typical functions of the thyroid gland, and by rapid, infiltrative, and destructive growth. Although it accounts for only a small percentage of all thyroid neoplasms, anaplastic carcinoma is responsible for a disproportionate share of thyroid cancer-specific mortality because of its fulminant course and frequent presentation at an advanced stage. The disease predominantly affects older individuals and often develops through the dedifferentiation of a pre-existing thyroid carcinoma or a long-standing nodular thyroid disorder.
The natural history of anaplastic thyroid carcinoma is characterized by extremely rapid progression, with early invasion of adjacent cervical structures, extensive lymph node involvement, and distant metastatic dissemination, particularly to the lungs, bones, and brain. The clinical presentation is typically dramatic, with rapid enlargement of the neck, pain, dysphagia, dyspnea, and voice changes caused by infiltration of the recurrent laryngeal nerve. Unlike differentiated and medullary thyroid carcinomas, anaplastic carcinoma does not benefit from radioiodine therapy and shows a limited response to conventional therapeutic strategies. Diagnosis and staging require a prompt and integrated approach that includes clinical assessment, advanced imaging, and histological confirmation, often obtained through core needle or surgical biopsy.
The treatment of anaplastic thyroid carcinoma is complex and typically multimodal, with goals that are often palliative rather than curative. Management requires a highly specialized multidisciplinary approach involving endocrinologists, surgeons, medical oncologists, radiation oncologists, and palliative care specialists. Despite advances in the molecular understanding of the disease and the introduction of targeted therapies in selected patient subgroups, the prognosis remains extremely poor, making early diagnosis of differentiated thyroid tumors and prevention of their dedifferentiated progression a priority.
The epidemiology of anaplastic thyroid carcinoma is characterized by a low incidence but an extremely substantial clinical and prognostic impact. Globally, this neoplasm represents a very small proportion of thyroid tumors, yet it is responsible for most deaths related to thyroid cancer. Over recent decades, a slight reduction in incidence has been observed in countries with advanced healthcare systems, probably because earlier diagnosis and more effective treatment of differentiated thyroid diseases reduce the risk of dedifferentiated transformation.
From a demographic perspective, anaplastic carcinoma almost exclusively affects individuals of advanced age, with peak incidence after the sixth to seventh decades of life. The sex distribution shows a slight female predominance, partly reflecting the higher prevalence of thyroid disorders among women. Advanced age at diagnosis is one of the main adverse prognostic determinants because it is frequently associated with significant comorbidities and reduced tolerance of aggressive treatments.
One of the main recognized risk factors is the presence of a pre-existing thyroid disorder, particularly a long-standing multinodular goiter or differentiated thyroid carcinoma. In many cases, anaplastic carcinoma develops through a process of tumor dedifferentiation in which a papillary or follicular carcinoma progressively acquires more aggressive biological characteristics. This evolution is driven by the accumulation of genetic and molecular alterations that result in loss of proliferative control and increased local invasiveness.
Unlike other thyroid tumors, there is no clear association between anaplastic carcinoma and exposure to ionizing radiation during childhood. Instead, a central role is played by late molecular events, such as mutations in genes involved in cell-cycle regulation and genomic stability. Alterations in TP53, mutations in BRAF or RAS, and aberrant activation of proliferative signaling pathways are frequently detected and contribute to the highly aggressive phenotype of the neoplasm.
Environmental and nutritional factors have not been identified as specific determinants of anaplastic carcinoma, although chronic iodine deficiency and limited access to healthcare may promote delayed diagnosis of underlying thyroid disorders, creating a setting in which dedifferentiation may occur. Overall, anaplastic thyroid carcinoma emerges as a neoplasm more closely related to the biological evolution of pre-existing thyroid diseases than to specific environmental exposures.
Taken together, these elements outline an epidemiological profile in which anaplastic carcinoma represents the extreme outcome of a thyroid neoplastic process, emphasizing the importance of prompt diagnosis and treatment of differentiated forms to reduce the risk of aggressive transformation.
There are no population-based screening programs for anaplastic thyroid carcinoma, nor are there specific surveillance strategies aimed at its early detection. The rarity of the disease and the speed of its progression make any dedicated screening approach impracticable. Furthermore, no biochemical markers or non-invasive tests are available that can reliably identify anaplastic transformation during the preclinical phase.
Secondary prevention is based mainly on the early diagnosis and appropriate management of differentiated thyroid diseases. Prompt treatment of suspicious thyroid nodules and differentiated carcinomas reduces the likelihood of dedifferentiated progression over time. In this context, neck ultrasonography and fine-needle aspiration cytology are essential tools for the early detection of thyroid neoplasms with potential for progression.
In patients with a history of differentiated thyroid carcinoma or long-standing multinodular goiter, the onset of clinical signs of rapid progression, such as sudden neck enlargement, pain, or compressive symptoms, should prompt immediate diagnostic reassessment. In these cases, clinical surveillance is not intended as screening but enables timely recognition of possible anaplastic transformation.
After anaplastic carcinoma has been diagnosed, surveillance takes on a different meaning and is directed primarily toward the assessment of treatment response and symptom control. Follow-up is generally brief and intensive, with serial imaging to monitor local and metastatic progression and particular attention to the management of respiratory and nutritional complications.
Overall, the absence of effective screening strategies makes an indirect preventive approach essential, based on the management of thyroid disorders at risk and careful clinical surveillance of individuals with a history of thyroid disease. Early identification of signs of dedifferentiation represents the only practical opportunity to intervene while this otherwise rapidly lethal neoplasm is still manageable.
The biology of anaplastic thyroid carcinoma reflects an extreme dedifferentiation of thyroid cells, with almost complete loss of the functional and morphological characteristics of the follicular epithelium. This neoplasm is one of the most aggressive human solid tumors and is characterized by rapid growth, early local invasiveness, and a marked tendency toward distant dissemination. In many cases, anaplastic carcinoma develops in a pre-existing differentiated thyroid carcinoma or chronic thyroid disorder, representing the terminal event of biological progression.
Its pathogenesis is based on the sequential accumulation of genetic alterations that lead to loss of differentiation programs and activation of uncontrolled proliferative and anti-apoptotic pathways. Tumor cells lose the ability to synthesize thyroglobulin and express the sodium iodide symporter, making radioactive iodine-based therapies ineffective. At the same time, transcriptional programs associated with cellular plasticity, invasiveness, and stress resistance are activated, conferring a highly malignant biological behavior on the tumor.
From a genetic perspective, anaplastic thyroid carcinoma displays marked genomic instability, with a high number of point mutations, deletions, amplifications, and complex chromosomal rearrangements. TP53 mutations are extremely frequent and represent a pivotal event in the loss of cell-cycle control and impairment of DNA repair mechanisms. Alterations in genes of the PI3K/AKT/mTOR pathway, mutations in BRAF or RAS, and amplifications of oncogenes such as MYC contribute to proliferative dysregulation and cell survival. TERT mutations are present in some cases and are associated with telomere instability and a particularly poor prognosis.
Epigenetic alterations play an important role in maintaining dedifferentiation. Changes in DNA methylation and chromatin structure result in the silencing of genes involved in thyroid differentiation and the activation of embryonic or mesenchymal programs. Dysregulation of microRNAs involved in controlling cellular identity and invasiveness promotes epithelial-mesenchymal transition, giving tumor cells a high migratory and invasive capacity.
The tumor microenvironment is profoundly altered. Rapid growth causes extensive areas of necrosis and hypoxia, with activation of HIF-1α and disorganized angiogenic programs. The stroma is rich in activated fibroblasts, inflammatory cells, and pro-inflammatory mediators that amplify biological aggressiveness. Extracellular matrix remodeling, mediated by metalloproteinases, facilitates infiltration of adjacent tissues, including the trachea, esophagus, muscles, and vascular structures of the neck.
From an immunological perspective, anaplastic carcinoma has a markedly immunosuppressive microenvironment. The lymphocytic infiltrate is often ineffective and dominated by cells with a dysfunctional phenotype. The expression of immunoregulatory molecules and the production of inhibitory cytokines limit cytotoxic activity, contributing to rapid disease progression.
From a biological perspective, the following forms are recognized:
From a histological perspective, anaplastic carcinoma displays a broad morphological spectrum. The cells may appear as multinucleated giant cells, sarcomatoid spindle cells, or undifferentiated pleomorphic cells, often associated with extensive necrosis and a high mitotic index. The architecture is chaotic, with complete loss of follicular organization. Histological variants do not substantially modify the prognosis, which remains poor across all subtypes.
Immunohistochemistry demonstrates loss of thyroid differentiation markers, such as thyroglobulin and TTF-1, while focal expression of cytokeratins may persist. The Ki-67 proliferation index is generally very high. Assessment of vascular and perineural invasion documents the marked infiltrative capacity of the tumor.
Overall, anaplastic thyroid carcinoma represents the outcome of extreme biological progression, characterized by genomic instability, epigenetic dedifferentiation, destructive interaction with the microenvironment, and loss of all proliferative control. These features explain its fulminant growth, resistance to conventional treatments, and extremely poor prognosis.
The clinical manifestations of anaplastic thyroid carcinoma are typically dramatic and rapidly progressive. The disease often presents as a rapidly enlarging cervical mass that develops over a period of weeks or a few months, sometimes within a thyroid gland previously affected by benign nodules or a known differentiated carcinoma. Sudden onset and fulminant progression are distinctive features of this neoplasm.
The tumor presents as a hard, poorly defined swelling that is frequently fixed to the deep planes. Rapid enlargement causes important compressive symptoms at an early stage. Tracheal compression causes progressive dyspnea, inspiratory stridor, and a sensation of suffocation, often exacerbated in the supine position. Dysphagia results from compression or infiltration of the esophagus and may rapidly progress to an inability to take food orally.
Local symptoms reflect invasion of cervical structures:
Neck pain is common and may radiate to the ears or shoulders. The overlying skin may appear tense, erythematous, or infiltrated. Rapid invasion of the soft tissues causes marked functional impairment of the neck, with restricted movement and a constant sensation of constriction.
Regional lymphatic spread is common at diagnosis, with hard and often bulky lateral cervical lymphadenopathy. Distant metastases are frequent and may already be present at onset, particularly in the lungs, bones, and brain. Systemic symptoms depend on the metastatic sites and include dyspnea, bone pain, focal neurological deficits, and seizures.
At a systemic level, anaplastic carcinoma is rapidly associated with deterioration of the general condition, including marked fatigue, rapid weight loss, anorexia, and low-grade fever. Cancer cachexia may develop within a short period, contributing to a drastic reduction in physical performance. Unlike other thyroid neoplasms, the endocrine function of the gland is clinically irrelevant, and patients are often euthyroid.
Physical examination reveals a hard, irregular, and poorly mobile cervical mass, often associated with signs of airway compression. Clinical assessment frequently identifies severe dysphonia, dyspnea, and dysphagia. The overall picture is that of an older patient with a history of thyroid disease who rapidly develops a cervical compressive syndrome accompanied by systemic signs of advanced disease.
Overall, anaplastic thyroid carcinoma is distinguished by an aggressive and rapidly progressive clinical presentation in which local symptoms dominate the picture and require immediate diagnostic and therapeutic assessment, often in the setting of a clinical emergency.
The diagnostic evaluation of anaplastic thyroid carcinoma begins with an urgent clinical suspicion and proceeds through a sequence of investigations intended first to provide histological confirmation of the anaplastic nature of the neoplasm, then to exclude alternative diagnoses, and finally to define the extent of disease without yet assigning a formal stage. Clinical suspicion typically arises in the presence of a rapidly worsening cervical mass, often painful and associated with acute compressive symptoms such as dysphagia, dyspnea, dysphonia, inspiratory stridor, or radiating neck pain. Systemic signs such as rapid weight loss, marked fatigue, and low-grade fever are not uncommon. Most patients experience clinical deterioration over a period of weeks, constituting a genuine oncological emergency.
Physical examination frequently reveals a hard, irregular thyroid swelling that is poorly mobile or fixed to the deep planes, with possible skin infiltration and palpable cervical lymphadenopathy. In this setting, the aim of the initial assessment is to rapidly recognize a clinical picture highly suggestive of anaplastic carcinoma and activate an expedited diagnostic pathway, avoiding delays that could compromise the possibility of even palliative therapeutic intervention.
Neck ultrasonography is the first-line imaging examination and can demonstrate a large thyroid mass that is often heterogeneous and hypoechoic, with irregular margins and signs of invasion of adjacent structures. Ultrasonography also provides a preliminary assessment of the cervical lymph node compartments, although anatomical complexity may limit its accuracy in advanced cases.
Thyroid fine-needle aspiration (FNA) or, when necessary, a core needle biopsy are essential steps in diagnostic confirmation. In anaplastic carcinoma, cytology demonstrates markedly pleomorphic cells, often giant or spindle-shaped, with a high mitotic index, extensive necrosis, and complete loss of the features of thyroid differentiation. When specimens are poorly cellular or inconclusive, a larger histological biopsy is indicated to ensure a definitive diagnosis.
Histological examination establishes the definitive diagnosis by documenting a very high-grade undifferentiated neoplasm with disorganized architecture, diffuse necrosis, and aggressive infiltration of the surrounding tissues. Immunohistochemistry plays an essential role in the differential diagnosis, typically showing loss of thyroid differentiation markers such as thyroglobulin and TTF-1, with possible expression of cytokeratins and non-specific markers. This profile makes it possible to distinguish anaplastic carcinoma from thyroid lymphomas, metastases from undifferentiated extrathyroidal carcinomas, and other rare neoplasms of the neck.
According to the main international guidelines, establishing a diagnosis of anaplastic thyroid carcinoma requires a minimum set of clinical and pathological findings which, although they do not constitute formal “diagnostic criteria,” represent essential requirements for a reliable diagnosis:
Elements required to establish a diagnosis of anaplastic thyroid carcinoma
Once the diagnosis has been confirmed, the differential diagnosis must include primary thyroid lymphoma, poorly differentiated thyroid carcinoma, metastasis from an undifferentiated carcinoma arising at another site, and neck sarcomas. Integration of the clinical findings, histology, and immunohistochemistry allows clear distinction in most cases.
After the diagnosis has been completed, investigations immediately focus on the assessment of disease extent. Contrast-enhanced computed tomography of the neck and chest is essential for assessing invasion of the airways, esophagus, and major vessels and for detecting pulmonary metastases. 18F-FDG PET provides a comprehensive assessment of systemic disease extent and rapidly identifies distant sites, which are frequently present at diagnosis. In patients with respiratory signs, laryngoscopy and bronchoscopy are useful for documenting involvement of the upper and lower airways.
In summary, the diagnostic pathway for anaplastic thyroid carcinoma follows an urgent sequence: recognition of clinical suspicion; neck ultrasonography; fine-needle aspiration or biopsy; histological and immunohistochemical confirmation; followed by rapid assessment of disease extent using CT, PET, and targeted endoscopic examinations.
The purpose of staging anaplastic thyroid carcinoma is to provide a standardized description of the anatomical extent of the disease and prognostic guidance, despite a clinical setting characterized by extreme aggressiveness and rapid progression. The international reference system is the eighth edition of the AJCC/UICC TNM classification, which recognizes the intrinsically advanced nature of this neoplasm.
In anaplastic carcinoma, all tumors are classified as T4 by definition because of local invasion or their highly aggressive biological behavior. Clinical and pathological staging therefore depends mainly on lymph node status and the presence of distant metastases.
Conceptually, the stage groups according to the eighth edition of the AJCC/UICC classification are as follows:
Stage groups in anaplastic thyroid carcinoma (AJCC/UICC eighth edition)
The prognosis of anaplastic thyroid carcinoma is extremely poor. Median survival is generally less than one year after diagnosis, with very low 1-year survival rates and rare exceptions among tumors diagnosed early and amenable to aggressive multimodal treatment.
The main prognostic determinants include the local extent of the disease, the presence of distant metastases at diagnosis, the possibility of achieving complete surgical resection, and the patient’s general condition. An emerging role is played by molecular alterations, particularly the presence of activating BRAF mutations, which in some cases allow the use of targeted therapies with a substantial effect on disease control.
Despite recent therapeutic advances, anaplastic carcinoma remains one of the most aggressive neoplasms in oncology. In most cases, the clinical objective focuses on symptom control, prevention of local complications, and preservation of quality of life through an integrated multidisciplinary approach.
The treatment of anaplastic thyroid carcinoma represents one of the most complex challenges in endocrine oncology because of its extreme biological aggressiveness, rapid local and systemic progression, and generally poor prognosis. The therapeutic approach must be immediate, intensive, and multidisciplinary, integrating surgery, radiotherapy, chemotherapy, and targeted systemic therapies, with continuous reassessment of the goals of care among curative intent, local control, and symptom palliation. The strategy depends critically on the extent of disease at diagnosis, resectability, molecular profile, and the patient’s general condition.
Surgery retains a central role only in the rare cases of localized and resectable disease at diagnosis. In these selected patients, the objective is complete macroscopic resection, which may require extensive procedures involving adjacent structures such as the trachea, esophagus, prethyroid muscles, and nerves, with a high risk of morbidity. Surgery alone is insufficient and must be incorporated into a multimodal strategy. However, when an R0 or R1 resection can be achieved, it may improve local control and, in selected cases, survival.
In most patients, the disease is already locally advanced or unresectable at presentation. In this setting, combined chemoradiotherapy represents a fundamental strategy for locoregional control. External-beam radiotherapy is administered at high doses, within the tolerance limits of critical organs, and is often combined with radiosensitizing chemotherapy. The primary objective is to slow local progression, reduce the risk of compressive complications, and improve symptom control rather than achieve a cure.
Systemic chemotherapy, used alone or in combination with radiotherapy, has historically shown limited survival benefits but retains a role as a component of combined regimens. Traditional cytotoxic agents are used mainly for radiosensitizing or palliative purposes, with careful attention to their toxicity profile in patients who are often frail and experience rapid deterioration of their general condition.
In recent years, the introduction of targeted therapies has significantly changed the therapeutic landscape in selected patient subgroups. In the presence of specific molecular alterations, particularly activating BRAF mutations, the use of targeted inhibitors, often in combination, may produce rapid and clinically meaningful responses, sometimes achieving sufficient tumor shrinkage to permit more effective subsequent locoregional treatment. Molecular characterization of the tumor therefore plays a crucial role and should be performed as early as possible.
In metastatic disease, the aim of treatment is predominantly palliative and is directed toward prolonging survival and, above all, preserving quality of life. Systemic therapies are selected according to the rate of progression, disease burden, molecular profile, and patient preferences, while avoiding disproportionate treatments when no meaningful clinical benefit is expected.
An essential aspect of treatment is the management of local complications, particularly the risk of airway obstruction. Early assessment of tracheal patency is essential and may require urgent interventions, such as tracheostomy or debulking procedures, primarily for palliative purposes. Similarly, dysphagia, pain, and bleeding require prompt and integrated symptomatic management.
At all stages of the disease, palliative support should be integrated early into the care pathway. Multidimensional management that includes pain control, nutritional support, respiratory management, and psychological care is essential for preserving the patient’s dignity, comfort, and residual autonomy, regardless of the intensity of active oncological treatment.
Follow-up and post-treatment surveillance of anaplastic thyroid carcinoma differ substantially from those of other thyroid neoplasms because of the high aggressiveness, rapid clinical progression, and absence of reliable specific biochemical markers. Surveillance is therefore predominantly clinical and radiological, with the objective of monitoring treatment response, detecting progression at an early stage, and promptly managing complications.
In patients who have undergone locoregional treatment, the initial assessment of response is performed using serial imaging, primarily computed tomography of the neck, chest, and, when indicated, abdomen. Assessments are generally performed at short intervals, particularly during the first few months, because of the high probability of early progression. Magnetic resonance imaging may be used in selected cases to better define local disease extent.
Clinical examination retains a central role in follow-up, particularly for the assessment of signs of airway compression, dysphagia, neck pain, and rapid deterioration of the general condition. Even minor changes in symptoms may reflect substantial progression and require immediate reassessment of the therapeutic strategy.
In patients receiving targeted systemic therapies, follow-up includes regular assessment of the radiological response and toxicity profile. Monitoring must be careful because cardiovascular, cutaneous, gastrointestinal, and metabolic adverse effects may substantially affect quality of life and require rapid treatment adjustments.
In the absence of specific serum markers, there is no routine role for biochemical tumor tests. Laboratory examinations are used mainly to monitor the patient’s general condition, organ function, and treatment tolerance rather than as tools for direct oncological surveillance.
A central element of follow-up is the continuous reassessment of the goals of care. Given the often limited prognosis, the surveillance pathway must remain flexible and patient-centered, adapting the intensity of assessments and treatments to the clinical course and the patient’s preferences. In many cases, follow-up progressively becomes integrated with a pathway of advanced palliative care.
The duration of follow-up is not defined according to standard time intervals but is closely related to the course of the disease. In the rare patients who achieve prolonged disease control, surveillance nevertheless remains frequent because of the high probability of recurrence. In cases of rapid progression, follow-up focuses predominantly on symptom control and comprehensive support.
In summary, follow-up of anaplastic thyroid carcinoma is not primarily intended to identify late recurrences but to provide continuous monitoring of the evolution of a highly aggressive disease. A patient-centered approach integrating clinical and radiological surveillance with supportive care is essential for achieving the best possible balance between disease control and quality of life.
Long-term quality-of-life considerations in anaplastic thyroid carcinoma have distinctive features related to the extreme biological aggressiveness of the disease, the rapidity of its clinical progression, and the intensity of the treatments required. In the rare patients who achieve prolonged survival or disease stabilization, quality of life becomes a priority and complex objective that is strongly influenced by functional outcomes and the psychological burden of the therapeutic pathway.
A central element is respiratory function. Direct involvement of the trachea and deep cervical structures, as well as the consequences of extensive surgical procedures or high-dose radiotherapy, may cause chronic dyspnea, reduced exercise tolerance, and, in some cases, dependence on a tracheostomy. These conditions profoundly affect personal autonomy, communication, and the patient’s sense of safety.
Swallowing and nutritional function are frequently impaired. Dysphagia, which is often early and progressive, may persist even in patients who achieve local disease control, making prolonged enteral nutrition necessary. Weight loss, sarcopenia, and malnutrition directly affect physical strength, functional capacity, and overall well-being, requiring continuous and highly individualized nutritional support.
Voice and communication changes represent an additional limiting factor. Severe dysphonia or aphonia, caused by tumor infiltration or injury to the laryngeal nerves, may impair verbal expression, with substantial effects on social relationships and personal identity. In patients who undergo tracheostomy, communication requires complex adaptations and dedicated rehabilitation support.
The psychological and emotional sphere is profoundly affected. Awareness of a generally poor prognosis, the intensity of treatment, and the speed with which disabling symptoms may develop result in high levels of anxiety, emotional distress, and depression. In patients who experience a meaningful therapeutic response, persistent psychological vulnerability may emerge because of fear of rapid progression and the need for frequent assessments.
The consequences of systemic treatments, including targeted therapies and chemotherapy, may include chronic toxicities such as marked fatigue, peripheral neuropathy, and cutaneous changes, which further impair quality of life. Management of these effects requires a constant balance between disease control and treatment tolerability.
Overall, long-term quality of life in anaplastic thyroid carcinoma depends on the healthcare system’s ability to provide comprehensive and anticipatory care that integrates symptom control, nutritional and respiratory support, psychological care, and, when indicated, early palliative care. In this context, quality of life represents a priority clinical outcome that often takes precedence over indicators of oncological control.
The complications of anaplastic thyroid carcinoma result from the combination of rapidly invasive tumor growth, critical involvement of cervical structures, and high-intensity treatments, creating an extremely complex clinical picture. They may develop early and cause rapid deterioration of the patient’s general condition.
Local progression of the tumor is one of the main sources of complications. Infiltration of the trachea, esophagus, and major vessels of the neck may cause acute dyspnea, severe dysphagia, potentially fatal hemorrhage, and irreversible impairment of vital functions. Compression or invasion of the laryngeal nerves causes dysphonia and a high risk of aspiration, while mediastinal extension may worsen respiratory symptoms.
Distant metastases, which are frequent and often occur early, mainly involve the lungs, bones, and brain. These sites may cause severe pain, pathological fractures, neurological deficits, and respiratory failure, substantially contributing to worsening prognosis and functional decline.
Surgery, when feasible, carries a high risk of complications. Extensive resections may result in cervical hematomas, infections, fistulas, multiple nerve injuries, and the need for permanent tracheostomy. In the setting of locally advanced disease, surgery often has a palliative intent, and its potential benefit must be carefully balanced against the risk of significant morbidity.
Radiotherapy, administered at high doses over large treatment volumes, may cause substantial acute and late toxicity. Complications include severe mucositis, esophagitis, radiation dermatitis, cervical edema, and worsening dysphagia. Late effects may include soft-tissue fibrosis, esophageal strictures, and permanent damage to the laryngotracheal structures.
Systemic treatments, including chemotherapy and targeted therapies, are associated with significant toxicities. Cytopenias, opportunistic infections, cardiovascular toxicity, gastrointestinal disorders, and marked fatigue are common and may limit the ability to continue treatment. In patients receiving targeted therapies, cutaneous reactions and metabolic abnormalities require intensive monitoring.
At a systemic level, cancer cachexia, recurrent infections, and thromboembolic events are frequent complications and important determinants of the clinical course. Rapid functional decline often makes an early palliative approach necessary, directed toward symptom control and preservation of the patient’s dignity.
Management of complications is based on prevention and timely identification, including close clinical monitoring, nutritional and respiratory support, pain control, and multidisciplinary integration of oncological, surgical, radiation oncology, and palliative care expertise. This approach reduces suffering, improves residual quality of life, and allows the goals of care to be appropriately adapted to the course of the disease.